Alx oncology doses first patient in phase 1 dose escalation trial evaluating adc alx2004 for the treatment of egfr-expressing solid tumors

- a potential best- and first-in-class antibody-drug conjugate (adc) for the treatment of egfr-expressing solid tumors, alx2004 is uniquely designed with every component optimized to maximize the therapeutic window -first-in-human trial of alx2004 builds upon body of positive preclinical data demonstrating dose dependent anti-tumor activity and favorable safety profile -initial safety data anticipated in first half 2026 south san francisco, calif., aug. 19, 2025 (globe newswire) -- alx oncology holdings inc., ("alx oncology" or the"company") (nasdaq: alxo), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that the first patient has been dosed in the company's phase 1 clinical trial for alx2004, a potential best- and first-in-class, epidermal growth factor receptor (egfr) adc that is being studied for the treatment of egfr-expressing solid tumors.
ALXO Ratings Summary
ALXO Quant Ranking